Efficacy and safety results from the Phase 2 clinical trial of pritelivir versus foscarnet for treatment of acyclovir-refractory and/or resistant mucocutaneous HSV infections in immunocompromised subjects (IDWeek 2025) - Sep 3, 2025 - Abstract #233; Pres time: Oct 20, 2025; 03:51 PM - 04:03 PM; Location: B213-B214; No abstract available
Clinical • P2 data • Herpes Simplex • Infectious Disease
|
|
Camille N. Kotton, MD, FIDSA, FAST; Robin K. Avery, MD; Kimberly Workowski, MD; Princy N. Kumar, MD; Joerg Albrecht, MD/PhD; Pranatharthi Chandrasekar, md; Mayur Ramesh, MD; Anna Wald, MD, MPH; Alexander Birkmann, PhD (he/him/his); Melanie E. Sumner, MSc; Bernadette Surujbally, MSc; Cynthia Wat, MBBS MRCP MFPM; Roy F. Chemaly, MD, MPH, FACP, FIDSA, FESCMID
|